{"id":58864,"date":"2026-06-01T09:16:57","date_gmt":"2026-06-01T07:16:57","guid":{"rendered":"https:\/\/setterwalls.se\/?post_type=assignments&#038;p=58864"},"modified":"2026-06-01T09:16:57","modified_gmt":"2026-06-01T07:16:57","slug":"setterwalls-advises-cantargia-in-connection-with-a-capital-raise-of-approximately-sek-124-million-and-entering-into-a-loan-agreement","status":"publish","type":"assignments","link":"https:\/\/setterwalls.se\/en\/case\/setterwalls-advises-cantargia-in-connection-with-a-capital-raise-of-approximately-sek-124-million-and-entering-into-a-loan-agreement\/","title":{"rendered":"Setterwalls advises Cantargia in connection with a capital raise of approximately SEK 124 million and entering into a loan agreement"},"content":{"rendered":"    <section class=\"block text bg-white\">\n        <div class=\"container container-sm\">\n            <div class=\"row\">\n                <div class=\"col-12\">\n                    <div class=\"editor-content\">\n                                                <div class=\"--co-782 \" aria-label=\"7. Preamble (Engelska) Text med en rad Kr\u00e4ver svar \">\n<div class=\"-CL-813 \" data-automation-id=\"questionContent\">\n<div class=\"-Oj-256 \">\n<div class=\"-VN-277\">\n<p class=\"-F_-816\"><strong>Setterwalls advises Cantargia AB (publ) (\u201cCantargia\u201d), listed on Nasdaq Stockholm, in connection with a rights issue of shares of approximately SEK 124 million and entering into a loan agreement with Fenja Capital II A\/S of up to SEK 75 million.<\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"--co-782 \" aria-label=\"8. Description (Engelska) Flerradig text Kr\u00e4ver svar \">\n<div class=\"-CL-813 \" data-automation-id=\"questionContent\">\n<div id=\"QuestionId_r2f476fbd73dc48a4b950830456506569\" class=\"-pG-266\">\n<p class=\"-xh-267\" data-automation-id=\"questionTitle\">The transaction strengthens the company\u2019s financial position and supports the continued clinical development of Cantargia\u2019s antibody-based treatments for life-threatening diseases.<\/p>\n<p>Cantargia is a clinical-stage biotechnology company developing antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP. The company\u2019s shares are listed on Nasdaq Stockholm and is headquartered in Lund, Sweden.<\/p>\n<\/div>\n<\/div>\n<\/div>\n                    <\/div>\n                <\/div>\n            <\/div>\n        <\/div>\n    <\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":16,"featured_media":58754,"template":"","meta":{"_acf_changed":true,"_seopress_robots_primary_cat":"","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":""},"class_list":["post-58864","assignments","type-assignments","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/assignments\/58864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/assignments"}],"about":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/types\/assignments"}],"author":[{"embeddable":true,"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/users\/16"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/media\/58754"}],"wp:attachment":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/media?parent=58864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}